There are 412 resources available
104P - Quantification analysis of low-cost near infrared camera for breast cancer treatment-related lymphedema fluorescence imaging
Presenter: Bayu Brahma
Session: Lunch and Poster Display session
105P - Impact of the number of synchronous cancer lesions in Bulgarian patients with multiple breast cancer
Presenter: Slavyana Usheva
Session: Lunch and Poster Display session
106P - Incorporating religious and cultural background: Patient informed consent in the era of acellular dermal matrix breast reconstruction
Presenter: Kassandra Beltran
Session: Lunch and Poster Display session
107P - Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines
Presenter: Maria Carmela Vistal
Session: Lunch and Poster Display session
108TiP - CINDERELLA clinical trial: Using artificial intelligence-driven healthcare to enhance breast cancer locoregional treatment decisions
Presenter: Andre Pfob
Session: Lunch and Poster Display session
114P - Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
Presenter: Christian Jackisch
Session: Lunch and Poster Display session
115P - Neoadjuvant pyrotinib combined with trastuzumab, albumin paclitaxel, and carboplatin for HER2-positive early or locally advanced breast cancer: A single-arm phase II trial
Presenter: Mei Liu
Session: Lunch and Poster Display session
116P - Interim analysis of 300 patients with HER2+/HR+ early breast cancer enrolled in the multi-national, prospective, observational ELEANOR NIS treated with extended adjuvant neratinib in clinical routine
Presenter: Rupert Bartsch
Session: Lunch and Poster Display session
117P - Three-year invasive disease-free survival results from a phase 2 study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
Presenter: Dan Zheng
Session: Lunch and Poster Display session
118P - A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2-positive (HER2+) early breast cancer in China: NER-Tree study - An interim analysis on patient characteristics and pretreatment patterns
Presenter: Jin Zhang
Session: Lunch and Poster Display session